Patents by Inventor John Keana

John Keana has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KW-3902 CONJUGATES THAT DO NOT CROSS THE BLOOD-BRAIN BARRIER
    Publication number: 20080070934
    Abstract: The present invention relates to certain compounds and to methods for the preparation of certain compounds that can be used in the fields of chemistry and medicine. Specifically, described herein are methods for the preparation of various compounds and intermediates, and the compounds and intermediates themselves. More specifically, described herein are methods for synthesizing KW-3902 derivatives of Formula (I), (II), (III), (IV), (V), and (VI).
    Type: Application
    Filed: August 21, 2007
    Publication date: March 20, 2008
    Inventors: Mark Mugerditichian, Howard Dittrich, Brian Farmer, Thomas Murray, John Keana
  • Production of gossypol co-crystals
    Publication number: 20080021110
    Abstract: This invention relates to relates to methods for producing gossypol acetic acid co-crystals and (?)-gossypol acetic acid co-crystals. The invention also relates to pharmaceutical compositions comprising gossypol acetic acid co-crystals and (?)-gossypol acetic acid co-crystals and the use of gossypol acetic acid co-crystals and (?)-gossypol acetic acid co-crystals for inducing apoptosis in cells and for sensitizing cells to the induction of apoptotic cell death.
    Type: Application
    Filed: March 29, 2007
    Publication date: January 24, 2008
    Applicant: Regents of the University of Michigan
    Inventors: Shaomeng Wang, Jianyong Chen, John Keana, Ming Guo
  • Dipeptide apoptosis inhibitors and the use thereof
    Publication number: 20050192231
    Abstract: The present invention is directed to novel dipeptides thereof, represented by the general Formula I: where R1-R3 and AA are defined herein. The present invention relates to the discovery that compounds having Formula I are potent inhibitors of apoptotic cell death. Therefore, the inhibitors of this invention can retard or block cell death in a variety of clinical conditions in which the loss of cells, tissues or entire organs occurs.
    Type: Application
    Filed: April 7, 2005
    Publication date: September 1, 2005
    Inventors: John Keana, Sui Cai, John Guastella, Wu Yang, John Drewe, Eckard Weber
  • Substituted guanidines having high binding to the sigma receptor and the use thereof
    Patent number: 5502255
    Abstract: N,N-disubstituted-guanidines, e.g., of the formula ##STR1## wherein R and R' are substituted or unsubstituted hydrocarbon groups. Methods are provided for the treatment of psychosis and hypertension by administering an effective amount of an N,N'-disubstituted guanidine which, preferably, has a high affinity for the sigma receptor.
    Type: Grant
    Filed: February 23, 1993
    Date of Patent: March 26, 1996
    Assignee: State of Oregon acting by and through the Oregon State Board of Higher Education, acting for and on behalf of The Oregon Health Sciences University and The University of Oregon
    Inventors: John Keana, Eckard Weber
  • Method for treating hypertension with disubstituted granidine compounds
    Patent number: 5385946
    Abstract: N,N-disubstituted-guanidines, e.g., of the formula ##STR1## wherein R and R' are substituted or unsubstituted hydrocarbon groups. Methods are provided for the treatment of psychosis and hypertension by administering an effective amount of an N,N'-disubstituted guanidine which, preferably, has a high affinity for the sigma receptor.
    Type: Grant
    Filed: February 23, 1993
    Date of Patent: January 31, 1995
    Assignee: State of Oregon, acting by and through the Oregon State Board of Higher Education, acting for and on behalf of the Oregon Health Sciences University and the University of Oregon
    Inventors: John Keana, Eckard Weber